Reditux

What is Reditux?

Reditux, a biosimilar rituximab - the world’s first monoclonal antibody biosimilar was launched by Dr. Reddy’s in 2007. It is used to treat Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukaemia and Rheumatoid Arthritis. This monoclonal antibody has helped over half a million patients worldwide.

Storage Conditions

2-8 degrees Celsius (refrigerate), Do not freeze.

Presentation

Vial containing concentrate for solution for infusion.

Route of Administration

Intravenous (IV) (upon prescription only and administered by a healthcare provider.)

Indications

Non-Hodgkin’s Lymphoma (NHL):

NHL is a type of cancer that originates in the lymphatic system, affecting white blood cells called lymphocytes. It encompasses a variety of subtypes, with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL) being common forms. NHL can spread to other parts of the body, and treatment often includes chemotherapy, targeted therapies, and immunotherapy.

How Rituximab works?

Mechanism of Action

Rituximab is a chimeric murine/human monoclonal immunoglobulin G1 antibody that targets CD20, which is a B-cell differentiation marker. CD20 is a cell surface marker specifically found on late pre-B and mature B lymphocytes and is not found on other cell types or free in circulation. The only binding site for Rituximab is CD20 on B-cells. The binding of Rituximab to cell surface CD20 located on the B lymphocytes results in the destruction of the lymphocyte by three potential mechanisms: complement-dependent cytotoxicity, stimulation of apoptosis, and antibody-dependent cytotoxicity.